細胞治療薬の世界市場 (～2027年)：薬価・投与動向・臨床試験

世界の細胞治療薬の市場は、活発な臨床パイプラインや、YescartaやKymriahなどの治療薬の売上増加などの要因から、2027年までに400億米ドルを超える市場機会を有すると予測されています。細胞治療薬の研究および臨床上の進歩は短い期間で急激に加速しています。かつては骨髄移植に限定されていた細胞治療薬の分野ですが、現在では様々な臨床徴候において重要な進歩を達成できる準備が整えられており、このことは、過去2年間で臨床試験の数が50％以上増加していることにも反映されています。現在のところ、1,000種類以上の細胞治療薬がパイプラインにあり、25種類の治療薬が市場に出回っています。

当レポートでは、世界の細胞治療薬の市場を調査し、細胞治療薬の概要・分類・作用機序・利点、適応症、パイプライン薬および上市済み薬の分析、主要地域別の動向、COVID-19の影響、COVID-19細胞治療薬開発の動向、大学・研究機関・企業による取り組みなどをまとめています。

第1章 細胞治療薬の概要

第2章 細胞治療薬の分類

第3章 細胞治療薬の作用機序

第4章 細胞治療薬の製造

第5章 従来の治療薬に対する細胞治療薬の利点

第6章 個別化細胞治療薬の台頭

第7章 細胞治療薬の用途

• 循環器疾患
• 神経疾患
• 炎症性疾患
• 糖尿病

第8章 細胞治療薬の癌治療への応用

第9章 大学レベルでの細胞治療薬研究

第10章 細胞治療薬研究促進のための戦略的提携

第11章 臨床パイプライン

• フェーズ別
• 国/地域別
• 会社ごと
• 徴候別
• 患者セグメント別
• 投与経路別

第12章 COVID-19：細胞治療薬研究への影響

第13章 COVID-19細胞治療薬の臨床試験：フェーズ・企業別

第14章 細胞治療薬の臨床試験：企業・適応症・フェーズ別

第15章 世界の細胞治療薬市場の展望

• 現在の市場シナリオ
• 細胞源別
  • 人工多能性幹細胞（IPSC）
  • 骨髄
  • 臍帯血由来細胞

第16章 米国：細胞治療薬の投与・コストの分析

• Allocord
• Laviv
• Maci
• Clevecord
• Hemacord
• Ducord
• Provenge
• HPC・臍帯血（Clinimmune Labs, University of Colorado Cord Blood Bank）
• HPC・臍帯血（LifeSouth Community Blood Centers, Inc）
• HPC・臍帯血（Bloodworks）
• HPC・臍帯血（MD Anderson Cord Blood Bank）
• Gintuit
• Kymriah^*
• Yescarta^*
• Carticel

第17章 韓国：細胞治療薬の投与・コストの分析

• Cartistem
• Chondron
• KeraHeal
• Cellgram
• Cure Skin Injection

第18章 オーストラリア・欧州・日本：細胞治療薬の投与・コストの分析

• Holoclar（欧州）
• Yescarta（EU）
• Kymriah（EU）
• Temcell HS（日本）
• Chondrocytes-T-Ortho-ACI（オーストラリア）

第19章 世界の細胞療法市場シナリオ

• 米国
• 韓国
• 欧州
• 日本
• 中国
• その他

第20章 世界の細胞治療薬研究の進歩

第21章 Treg細胞：細胞治療薬の次のステップ

第22章 将来展望

第23章 上市済み薬の臨床的考察：企業・適応症別

• Tisagenlecleucel（Kymriah）
• Axicabtagene Ciloleucel（Yescarta）
• 同種培養ケラチノサイト・線維芽細胞（Gintuit）
• 脂肪幹細胞治療薬（Adipocell（Anterogen）、Cupistem＆Queencell）
• Tonogenchoncel-L（INVOSSA-K inj）
• 間葉系幹細胞治療薬（Stempeucel）
• Remestemcel-L（Prochymal＆TEMCELL HS Inj。）
• Sipuleucel-T（Provenge）
• 自家間葉系幹細胞治療薬：ファーミセル
• 自家培養軟骨細胞（MACI）
• 自家培養軟骨細胞（Chondrotransplant DISC）
• 自家角膜上皮幹細胞治療薬（Holoclar）
• Nalotimagene Carmaleucel（Zalmoxis）
• 軟骨修復のための間葉系幹細胞治療薬（Cartistem）
• 自己軟骨細胞インプラント：TETEC、など

第24章 競合情勢

• Athersys Inc.
• Baxter Healthcare Corporation
• Bone Therapeutics
• Celgene Corporation
• Cell Medica
• Cellerant Therapeutics
• FibrocellScinence
• Genzyme Corporation
• Green Cross Cell
• Histogenics Corporation
• Intrexon Corporation
• Intercytex
• ISTO Biologics
• Macrocure
• Mesoblast
• Molmed
• Nuo Therapeutics Inc
• OmniCyte
• Opexa Therapeutics
• Organogenesis
• Pharmicell
• TCA Cellular Therapy
• Stem Cell Inc.
• Teva Pharmaceuticals
• Tigenix
• Vericel Corporation

List of Figures

• Figure 1-1: Cell Therapy Pathway
• Figure 1-2: Evolution of Cell Therapy
• Figure 2-1: Types of Cell Therapy
• Figure 2-2: Steps in Allogeneic Cell Therapy
• Figure 2-3: Steps in Autologous Cell Therapy
• Figure 2-4: Steps in the Derivation of Human Embryonic Stem Cells
• Figure 2-5: Cardinal Neural Stem Cell Properties
• Figure 2-6: Mesenchymal Stem Cells Therapy Process
• Figure 3-1: Cell Therapy Mechanism
• Figure 4-1: Centralized Manufacturing Model
• Figure 4-2: Near Patient Manufacturing Model
• Figure 5-1: Major Steps in Cell Therapy
• Figure 5-2: Global- Expected Aging Population of 60+ (Billion), 2015 & 2050
• Figure 5-3: Advantages of Cell Therapy as a Rejuvenation Therapy
• Figure 6-1: Advantages of Personalized Cell Therapy
• Figure 6-2: Mesenchymal Stem Cells (MSCs) in Autism Spectrum Disorder (ASD) Treatment
• Figure 6-3: Steps of iPSC Transplantation
• Figure 7-1: Global-Mortality Caused by Non Communicable Disease (%)
• Figure 7-2: Cell Therapy for Cardiovascular Disease
• Figure 7-3: Overview of Stem Cell Therapy in Cardiovascular Disease
• Figure 7-4: Cell Therapy in Neurological Disorders
• Figure 7-5: Cell Therapy in Treatment of Alzheimer's disease
• Figure 7-6: Cell Therapy in Diabetes
• Figure 9-1: Clinical Trial Results, February'2020
• Figure 9-2: Clinical Trial Results (%), February'2020
• Figure 11-1: Global-Cell Therapies Clinical Pipeline by Phase (%), 2020 till 2027
• Figure 11-2: Global-Cell Therapies Clinical Pipeline by Phase (Number), 2020 till 2027
• Figure 11-3: Global-Cell Therapies Clinical Pipeline by Region (Number), 2020 till 2027
• Figure 11-4: Global-Cell Therapies Clinical Pipeline by Company (Number), 2020 till 2027
• Figure 11-5: Global-Cell Therapies Clinical Pipeline by Indication (Number), 2020 till 2027
• Figure 11-6: Global-Cell Therapies Clinical Pipeline by Patient Segment (Number), 2020 till 2027
• Figure 11-7: Global-Cell Therapies Clinical Pipeline by Route Of Administration (Number), 2020 till 2027
• Figure 13-1: Global-COVID-19 Cell Therapies Clinical Pipeline by Phase (%), 2020
• Figure 13-2: Global-COVID-19 Cell Therapies Clinical Pipeline by Phase (Number), 2020
• Figure 13-3: Global-COVID-19 Cell Therapies Clinical Pipeline by Company (Number), 2020
• Figure 13-4: Global-COVID-19 Cell Therapies Clinical Pipeline by Country (Number), 2020
• Figure 15-1: Cell Therapy- The Final Therapeutic Pillar of Healthcare
• Figure 15-2: Global-Cell Therapy Market (US$ Billion), 2019-2027
• Figure 15-3: Process for Conventional Drug Delivery
• Figure 15-4: Process for Induced Pluripotent Stem Cell Based Drug Delivery
• Figure 15-5: Global- Induced Pluripotent Stem Cell Therapy Market (US$ Billion), 2019-2027
• Figure 15-6: Steps involved in Bone Marrow Transplant
• Figure 16-1: US-Allocord Infusion per Hour (Millilitres), Adult & Children
• Figure 16-2: Allocord-Composition of Single Unit of Suspension for Injection (Million Cells)
• Figure 16-3: Laviv-FDA Approval & Patent Expiration Year
• Figure 16-4: Laviv-Cost of Single Treatment Cycle & Full Treatment Cost (US$), May'2020
• Figure 16-5: MACI-Mixed Cell Populations for Tissue Repair & Separation Technique Related Patent Issue & Expiration Year
• Figure 16-6: MACI-Administration Related Patent Issue & Expiration Year
• Figure 16-7: MACI-Method of Manufacturing Related Patent Issue & Expiration Year
• Figure 16-8: MACI-Cost for Treatment of Fractures & Cartilage Injury (US$), May'2020
• Figure 16-9: MACI-Cost for Treatment of Fractures & Cartilage Injury (US$), May'2020
• Figure 16-10: US-Clevecord Dosage of Nucleated Cells per Killogram (Million) & Average Cost (US$)
• Figure 16-11: Hemacord-Composition of Single Unit of Suspension for Injection (Million Cells)
• Figure 16-12: Ducord-Composition of Single Unit of Suspension for Injection (Million Cells)
• Figure 16-13: Provenge-Patent Issue & Expiration Year
• Figure 16-14: Provenge-Price of 250ml Supply & Price per ml (US$), May'2020
• Figure 16-15: Provenge-Price of Single Treatment Cycle & Price for Full Treatment (US$), May'2020
• Figure 16-16: HPC Cord Blood (Clinimmune Labs)-Composition of Single Unit of Suspension for Injection (Million Cells)
• Figure 16-17: Kymriah-FDA Approval Year by Indication
• Figure 16-18: Kymriah-Number of Patents by Region
• Figure 16-19: Kymriah-Number of US Patents by Nature of Patent
• Figure 16-20: US-Kymriah Average Dosage of CAR positive viable T cells (Paediatric & Adults), August 2017
• Figure 16-21: Kymriah-Cost of Intravenous Suspension & Additional Expenditure (US$), May'2020
• Figure 16-22: Kymriah-Minimum & Maximum Dose for Patients with Less than 50Kg Weight for ALL Management (Million Cells/ Kg), May'2020
• Figure 16-23: Kymriah-Minimum & Maximum Dose for Management of Large B-Cell Lymphoma (Million Cells/ Kg), May'2020
• Figure 16-24: Kymriah-Annual Sales Value (US$ Million), 2017-2019
• Figure 16-25: Global-Kymriah Quarterly Sales Value (US$ Million), 2019
• Figure 16-26: Yescarta-FDA Approval & US Patent Expiration Year
• Figure 16-27: US-Yescarta Target Dose vs Maximum Dose of CAR-positive viable T cells, October 2017
• Figure 16-28: Yescarta-Cost of Intravenous Suspension & Additional Expenditure (US$), May'2020
• Figure 16-29: Yescarta-Dose for Average Human & Maximum Dose (Million Cells), May'2020
• Figure 16-30: Yescarta-Annual Sales Value (US$ Million), 2017-2019
• Figure 16-31: Yescarta-Annual Sales Value by Region (US$ Million), 2019
• Figure 16-32: Yescarta-Annual Sales Value by Region (%), 2019
• Figure 16-33: Global-Yescarta Quarterly Sales Value (US$ Million), 2018 & 2019
• Figure 16-34: Carticel-FDA Approval & Patent Expiration Year
• Figure 16-35: US-Carticel Minimum & Maximum Cost (US$), October 2017
• Figure 17-1: Cartistem-Average Cost of Regenerative & Additional Treatment (US$), May'2020
• Figure 17-2: Cartistem-Annual Sales Value (KRW/US$ Million), 2012 & 2019
• Figure 17-3: Chondron-Average Cost of Knee Cartilage Defect Treatment (KRW/US$), May'2020
• Figure 17-4: South Korea-KeraHeal vs KeraHeal-Allo Dosage form (Miililitres Cell Suspension)
• Figure 17-5: Cellgram-Average Cost of Intravenous Suspension (KRW/US$), May'2020
• Figure 18-1: Holoclar-Cost of Single & Both Eyes Treatment (GBP/US$), May'2020
• Figure 18-2: Holoclar-Recommended Minimum & Maximum Dose (Cells/cm2 of Cornea Surface), May'2020
• Figure 18-3: Yescarta-FDA Approval, EU Approval & US Patent Expiration Year
• Figure 18-4: Yescarta-Cost of Intravenous Suspension & Additional Expenditure (EUR/US$), May'2020
• Figure 18-5: Yescarta-Dose for Average Human & Maximum Dose (Million Cells), May'2020
• Figure 18-6: Yescarta-Annual Sales Value (US$ Million), 2019'Q1 & 2020'Q1
• Figure 18-7: Yescarta-Annual Sales Value (US$ Million), 2017-2019
• Figure 18-8: Yescarta-Annual Sales Value by Region (US$ Million), 2019
• Figure 18-9: Yescarta-Annual Sales Value by Region (%), 2019
• Figure 18-10: Europe-Yescarta Quarterly Sales Value (US$ Million), 2019
• Figure 18-11: Kymriah-FDA Approval Year by Region
• Figure 18-12: Kymriah-Number of Patents by Region
• Figure 18-13: Kymriah-Cost of Intravenous Suspension & Additional Expenditure (EUR/US$), May'2020
• Figure 18-14: Kymriah-Minimum & Maximum Dose for Patients with Less than 50Kg Weight for ALL Management (Million Cells/ Kg), May'2020
• Figure 18-15: Kymriah-Minimum & Maximum Dose for Management of Large B-Cell Lymphoma (Million Cells/ Kg), May'2020
• Figure 18-16: Global-Kymriah Quarterly Sales Value (US$ Million), 2019'Q1 & 2020'Q1
• Figure 18-17: Kymriah-Annual Sales Value (US$ Million), 2017-2019
• Figure 18-18: Global-Kymriah Quarterly Sales Value (US$ Million), 2019
• Figure 18-19: Japan-Temcell Dosage of Cells per Killogram Body Weight (Million)
• Figure 18-20: Cost for Single Bag, Single Treatment Cycle & Full Treatment (JPY/US$), May'2020
• Figure 18-21: Australia-Ortho-ACI Constituents of Dulbecco's Modified Eagle Medium (DMEM) nutrient mixture
• Figure 18-22: Australia-Ortho-ACI Average Dose (Million Cells) & Cost of Treatment (US$)
• Figure 19-1: Significance of Cell Therapy Market Technology
• Figure 19-2: Drivers for Growth of Cell Therapy in Japan
• Figure 19-3: Criteria Impacting Successful Cell Therapy
• Figure 19-4: China Cell Therapy Market Strategy
• Figure 19-5: Rest of the World-Cell Therapy Clinical Trial by Region (%), 2019
• Figure 20-1: Signaling Pathway in Chronic Lymphocytic Leukemia
• Figure 20-2: Advantages of Treating Rheumatoid arthritis with Umbilical Cord Mesenchymal Stem Cells
• Figure 20-3: Stem Cell Therapy for the Treatment of Male Infertility
• Figure 20-4: Cell Therapy for Ptients with Angina
• Figure 20-5: Benefits of Stem Cell Therapy in Aesthetic Purposes
• Figure 21-1: Working of CD4+ & CD25+ Regulatory T-Cell
• Figure 21-2: Mechanism of Action of Treg Cell
• Figure 21-3: Therapeutic Action of Treg Cell
• Figure 21-4: Future Applications of Treg Cells
• Figure 22-1: Growth Opportunities for Cell Therapy
• Figure 24-1: Bone Therapeutics Clinical Pipeline
• Figure 24-2: Celgene Clinical Pipeline
• Figure 24-3: Cell Medica Therapeutics Clinical Pipeline
• Figure 24-4: Cellerant Therapeutics Clinical Pipeline
• Figure 24-5: Fibrocell Science Clinical Pipeline
• Figure 24-6: Intrexon Clinical Pipeline
• Figure 24-7: Mesoblast Clinical Pipeline
• Figure 24-8: Molmed Clinical Pipeline
• Figure 24-9: Tigenix Clinical Pipeline
• Figure 24-10: Vericel Corporation Clinical Pipeline

List of Tables

• Table 2-1: Difference between Allogeneic & Autologous Cell Therapy
• Table 5-1: Difference between Cell Therapy & Conventional Therapy
• Table 20-1: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
• Table 20-2: Targeted Therapy in Patients with Chronic Lymphocytic Leukemia
• Table 20-3: Results of Phase I-II Trials of Adoptive Cell Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant
• Table 21-1: Functions of Effector T-Cell & Treg Cell

"Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights:

• Global Cell Therapy Market Opportunity: More Than USD 40 Billion By 2027

• Cell Therapy Clinical Trial Insight by Indication, Company and Country

• Global Cell Therapy Clinical Pipeline: 1000 Cell Therapies

• Globally Marketed Cell Therapies: 25 Cell Therapies

• Cell Therapy Trials For COVID-19: 10 Cell Therapies

• Global COVID-19 Cell Therapy Clinical Trials By Phase & Company

• COVID-19 Impact Analysis on Global market & Clinical Trials

• Price & Product Insight By Region/Country

Over a period of time, cell therapy has emerged as next growth frontier for the pharmaceutical companies involved the research and development of innovative therapies for the treatment of simple to complex medical anomalies. The increasing focus on new technologies and methodologies are leading to path breaking innovations which are playing an important role in the practice of medicine and cell therapy. The cell therapy approach to treatment and prevention is more advanced and targeted as compare to traditional therapies as the former works at basic level on human science that is cells. Cell therapy treatment is more advanced and custom in nature and thus giving the required thrust to advancement of personalized therapy.

"Global Cell Therapy Market Opportunity To Surpass US$ 40 Billion by 2027 Driven By Robust Clinical Pipeline & Increasing Sales Of Therapies Like Yescarta & Kymriah"

Cell therapy research and clinical advancement has accelerated strongly in the limited period of time. Once limited to bone marrow transplants, the cell therapy field is currently prepared to achieve critical advances in various distinctive clinical signs. The same scenario can be reflected in the fact that the number of clinical trials have increased more than 50% in last 2 years. At present (June'2020), more than 1000 cell therapies are in pipeline and 25 therapies are commercially available in the market. Most of the cell therapies are in preclinical stage and close to 450 therapies are in Phase I, Phase II & Phase III trials. Analysis of the pipeline shows that the majority of cell therapy products that are currently under development are targeted towards treatment of complex disease like cardiovascular disease, neural disease and cancer.

The commercial acceptability and success of cell therapies can also be reflected from robust sales of therapies like Yescarta (Gilead Sciences) & Kymriah (Novartis). During 2019, the sales of Yescarta surpassed US$ 450 Million as compared to US$ 264 Million in 2018, with annual growth of almost 72%. Similarly, Kymriah witnessed growth of 260% with total sales of more than US$ 270 Million in 2019 as compare to less than US$ 75 Million in 2018. Further, the rapid approval and orphan status of few therapeutics coming out of the cell therapy pipeline ensures it to be a lucrative segment. Several collaborations in the past few years has created an optimistic scenario when it comes to the future of cell therapy segment. The cell therapy industry is rapidly growing industry with the several new products that having been accepted for clinical use over the past few years. There are many challenges that need to be resolved wisely before the cell therapies are widely accepted, including the optimization of their manufacture.

With increasing number of clinical trials, robust sales values and widening clinical indication base, it is clear reflection of the fact that the cell therapy market will witness remarkable growth trajectory in coming years. The global cell therapy market opportunity is estimated to surpass US$ 40 Billion by 2027 driven by increasing technical and manufacturing capabilities coupled with the advancements that will drive the acceptability of cell therapy procedures among the various stakeholders of the pharmaceutical industry. The current scenario of COVID-19 may slowdown the clinical trials conductibility or the market growth trajectory but the same COVID-19 pandemic is going to offer new growth avenues to the industry in form of ongoing clinical trials for the treatment of COVID-19.

Table of Contents

1. Overview of Cell Therapy

• 1.1. Introduction to Cell Therapy
• 1.2. History & Evolution of Cell Therapy

2. Cell Therapy Classification

• 2.1. Allogeneic Cell Therapy
• 2.2. Autologous Cell Therapy
• 2.3. Human Embryonic Stem Cell Therapy
• 2.4. Neural Stem Cell Therapy
• 2.5. Mesenchymal Stem Cell Therapy
• 2.6. Hematopoietic Stem Cell Transplantation

3. Mechanism of Therapeutic Action in Cell Therapy

4. Manufacturing of Cell Therapies

• 4.1. Models for Manufacturing Cell Therapies
• 4.2. Facilities for Good Manufacturing Practice

5. Advantages of Cell Therapy Over Conventional Therapy

• 5.1. Anti-Aging with Cell Therapy
• 5.2. Addressing Other Diseases with Cell Therapy

6. Emergence of Personalized Cell Therapy

• 6.1. Overview of Personalized Cell Therapy
• 6.2. Personalized Cell Therapy Using Epigenetic Tools
• 6.3. Personalized Cell Therapy through Mesenchymal Stem Cells
• 6.4. Treatment of Parkinson's Disease through IPSCs
• 6.5. Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp Stem Cells & Leukocyte Platelet Rich Fibrin

7. Cell Therapy Application by Therapeutic Areas

• 7.1. Cardiovascular Disease
• 7.2. Neurological Disorders
• 7.3. Inflammatory Diseases
• 7.4. Diabetes

8. Application of Cell Therapy to Cancer Therapeutics

• 8.1. Stem Cells & Their Therapeutic Role in Cancer
• 8.2. Role of Surface Markers & Their Targeting

9. Cell Therapy Research Insights at University Level

• 9.1. Cell Therapy for Diabetes in Animal Model
• 9.2. Cell Therapy as a Renewable Treatment Source for Cancer
• 9.3. Advancing CAR T-Cell Therapy for Cancer Treatment
• 9.4. Improving Depth & Durability of Cancer Treatment by CAR T-Cell Therapy
• 9.5. NKTR-214 in Combination with Adoptive Cell Therapy Against Melanoma
• 9.6. Regenerative Medicine Advanced Therapy Designation Granted to CAR T-Cell Therapy by FDA
• 9.7. UCLA & CASIS Collaboration for Regenerative Medicine & Stem Cell Research
• 9.8. Dual Stem Cell Therapy for Cardiac Repair
• 9.9. T-Cell Therapy against Multiple Forms of Cancers
• 9.10. Stem Cell Therapy against Covid-19 Pandemic
• 9.11. AgeX Therapeutics & University of California Research Program for Huntington's Disease & Other Neurological Disorders
• 9.12. Avacta Group plc & Memorial Sloan Kettering Cancer Center Research Collaboration for CAR-T Cell-Based Immunotherapy.
• 9.13. Remodeled CAR-T Cell Therapy Undergoing Extensive Groundwork
• 9.14. Invariant Natural Killer Cell's Long-Lasting Immunity against Cancer Cells
• 9.15. Light Sensitive CAR-T Cells against Skin Tumor in Mice Resulted to be Effective
• 9.16. Scorpion Toxin to Guide CAR-T Cells for Brain Cancer

10. Strateging Alliances for Promoting Cell Therapy Research

• 10.1. GlaxoSmithKline's Deal with Immatics Cell Therapy Science to Advance Cell Therapy
• 10.2. Indapta Therapeutics & Lonza's New Partnership for Advancing Cancer Cell Therapy
• 10.3. Key Biologics & Blood Centers of America to Open Access for Cell Therapy
• 10.4. Gamida Regulatory Nods with Lonza for Cell Therapy Product Production
• 10.5. GlaxoSmithKline & Lyell Immunopharma to Develop Next Generation Cancer Cell Therapies
• 10.6. Harvard & MIT to Bolster Cell & Gene Therapy Medical Research
• 10.7. Takeda & MD Anderson to Accelerate the Development of NK Cell Therapy Platform
• 10.8. Multiple Cell Therapy Collaborations Initiated by Takeda Pharmaceuticals
• 10.9. Mesenchymal Stem Cell Program Launch By Celltex against Covid-19
• 10.10. Artisan Bio Announces Global Research & Takeda to Undergo Next-Generation Cell Therapy Products Development
• 10.11. Astellas & Universal Cells, Inc. Collaboration for Cell Therapy Product Development for Undisclosed Indication
• 10.12. Fate Therapeutics & Janssen to Undergo Worldwide Collaboration for iPSC-derived Cell-based Cancer Immunotherapies
• 10.13. Kite & Teneobio Collaboration for the Development of CAR-T Antibodies
• 10.14. Lonza to Undergo Series of Collaborations for the Development of Novel Cell Cancer Therapies
• 10.15. Other Latest Press Releases for Stem Cell Therapy Research & Development
  • 10.15.1. RegenMed Development Organization & CollPlant Business Alliance
  • 10.15.2. Institute of Integrative Biology & Anika Therapeutics Business Alliance
  • 10.15.3. The US FDA & Cytobank Collaboration Agreement

11. Global Cell Therapy Clinical Pipeline Overview

• 11.1. By Phase
• 11.2. By Country/Region
• 11.3. By Company
• 11.4. By Indication
• 11.5. By Patient Segment
• 11.6. By Route Of Administration

12. Impact of COVID-19 On Cell Therapy Research Landscape

13. Global COVID-19 Cell Therapy Clinical Trials By Phase & Company

• 13.1. Research
• 13.2. Preclinical
• 13.3. Clinical
• 13.4. Phase-I
• 13.5. Phase-I/II
• 13.6. Phase-II

14. Global Cell Therapies Clinical Pipeline By Company, Indication & Phase

• 14.1. Unknown
• 14.2. Research
• 14.3. Preclinical
• 14.4. Clinical
• 14.5. Phase-0
• 14.6. Phase-I
• 14.7. Phase-I/II
• 14.8. Phase-II
• 14.9. Phase-II/III
• 14.10. Phase-III
• 14.11. Preregistration
• 14.12. Registered

15. Global Cell Therapy Market Outlook

• 15.1. Current Market Scenario
• 15.2. Cell Therapy Market by Cell Source
  • 15.2.1. Induced Pluripotent Stem Cell (IPSCs)
  • 15.2.2. Bone Marrow
  • 15.2.3. Umbilical Cord Blood Derived Cells

16. US-Cell Therapy Dosage & Cost Analysis

• 16.1. Allocord
• 16.2. Laviv
• 16.3. Maci
• 16.4. Clevecord
• 16.5. Hemacord
• 16.6. Ducord
• 16.7. Provenge
• 16.8. HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
• 16.9. HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
• 16.10. HPC, Cord Blood (Bloodworks)
• 16.11. HPC, Cord Blood (MD Anderson Cord Blood Bank)
• 16.12. Gintuit
• 16.13. Kymriah^*
• 16.14. Yescarta^*
• 16.15. Carticel

17. South Korea-Cell Therapy Dosage & Cost Analysis

• 17.1. Cartistem
• 17.2. Chondron
• 17.3. KeraHeal
• 17.4. Cellgram
• 17.5. Cure Skin Injection

18. Australia, Europe & Japan-Cell Therapy Dosage & Cost Analysis

• 18.1. Holoclar (Europe)
• 18.2. Yescarta (EU)
• 18.3. Kymriah (EU)
• 18.4. Temcell HS (Japan)
• 18.5. Chondrocytes-T-Ortho-ACI (Australia)

19. Global Cell Therapy Market Scenario

• 19.1. US
• 19.2. South Korea
• 19.3. Europe
• 19.4. Japan
• 19.5. China
• 19.6. Rest of the World

20. Global Cell Therapy Research Advancements

• 20.1. Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia
• 20.2. Advances in Cytomegalovirus Infection Prevention & Treatment
• 20.3. Stem Cell Therapy for the Treatment of Parkinson's Disease
• 20.4. Stem Cell Therapy for the Treatment of Alzheimer's Disease
• 20.5. Treatment of Rheumatoid Arthritis via Stem Cell Therapy
• 20.6. Role of Stem Cell Therapy in Treating Infertility
• 20.7. Stem Cells for Eye Diseases
• 20.8. Cell Therapy for Stroke and Angina Pectoris
• 20.9. Stem Cell Therapy in Improving Wrinkles & Acne Scars

21. Treg Cells-The Next Step To Advance Cell Therapy

• 21.1. Introduction to Treg Cell
• 21.2. Isolation & Expansion of Treg Cell
• 21.3. Mechanism of Action
• 21.4. Clinical Trials of Treg Cell Therapy
  • 21.4.1. Adoptive Cell Therapy of Treg cells to Prevent GvHD
  • 21.4.2. Adoptive Cell Therapy of Polyclonal & Alloantigen-specific Treg cells to
  • Prevent Solid Organ Transplant Rejection
• 21.5. Treg Cell Therapy for the Treatmet of Autoinflammatory & Autoimmune Diseases
  • 21.5.1. Inflammatory Bowel Disease
• 21.5.2. Systemic Lupus Erythematosus
• 21.5.3. Autoimmune Hepatitis
  • 21.5.4. Pemphigus Vulgaris
  • 21.5.5. Allergy and Asthma
• 21.6. Future Prospects of Treg Cell Therapy

22. Global Cell Therapy Market Future Prospects

23. Marketed Cell Therapies Clinical Insight by Company & Indication

• 23.1. Tisagenlecleucel (Kymriah)
• 23.2. Axicabtagene Ciloleucel (Yescarta)
• 23.3. Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)
• 23.4. Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem & Queencell)
• 23.5. Tonogenchoncel-L (INVOSSA-K inj)
• 23.6. Mesenchymal Stem Cell Therapies (Stempeucel)
• 23.7. Remestemcel-L (Prochymal & TEMCELL HS Inj.)
• 23.8. Sipuleucel-T (Provenge)
• 23.9. Autologous Mesenchymal Stem Cell Therapy-Pharmicell
• 23.10. Autologous Cultured Chondrocytes (MACI)
• 23.11. Autologous Cultured Chondrocytes (Chondrotransplant DISC)
• 23.12. Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
• 23.13. Nalotimagene Carmaleucel (Zalmoxis)
• 23.14. Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)
• 23.15. Autologous Chondrocyte Implant-TETEC
• 23.16. Muscle-Derived Autologous Stem Cell Therapy (MyoCell)
• 23.17. Human Skin Replacement (CellSpray)
• 23.18. Leukocyte Cell Therapy (CureXcell)
• 23.19. Autologous Cultured Chondrocyte Implant (Carticel)
• 23.20. Azficel-T (Laviv)
• 23.21. Autologous Cultured Chondrocytes (CHONDRON)
• 23.22. Autologous Chondrocytes (BioCart)
• 23.23. Amniotic Cell Therapy (NuCel)
• 23.24. Dendritic Cell-Activated Cytokine-Induced Killer Cells-Shanghai Jia Fu Medical
• 23.25. Autologous Cultured Myoblasts And Fibroblasts (Urocell)

24. Competitive Landscape

• 24.1. Athersys Inc.
• 24.2. Baxter Healthcare Corporation
• 24.3. Bone Therapeutics
• 24.4. Celgene Corporation
• 24.5. Cell Medica
• 24.6. Cellerant Therapeutics
• 24.7. FibrocellScinence
• 24.8. Genzyme Corporation
• 24.9. Green Cross Cell
• 24.10. Histogenics Corporation
• 24.11. Intrexon Corporation
• 24.12. Intercytex
• 24.13. ISTO Biologics
• 24.14. Macrocure
• 24.15. Mesoblast
• 24.16. Molmed
• 24.17. Nuo Therapeutics Inc
• 24.18. OmniCyte
• 24.19. Opexa Therapeutics
• 24.20. Organogenesis
• 24.21. Pharmicell
• 24.22. TCA Cellular Therapy
• 24.23. Stem Cell Inc.
• 24.24. Teva Pharmaceuticals
• 24.25. Tigenix
• 24.26. Vericel Corporation